Sign in →

Epic Code LAB485 Primidone and Phenobarbital, Serum

Additional Codes

Mayo Code: PRMB

Epic Code: LAB 485

Interface: 10223

Cerner: 8234

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Useful For

Assessing compliance

 

Monitoring for appropriate therapeutic levels of primidone and phenobarbital

 

Assessing toxicity

Specimen Type

Serum


Specimen Required


Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions:

1. Serum gel tubes should be centrifuged within 2 hours of collection.

2. Red-top tubes should be centrifuged, and the serum aliquoted into a plastic vial within 2 hours of collection.


Laboratory Test Directory Note:

COLLECTION NOTE: Volumes listed are in serum or plasma, draw approximately 2 1/2 times the requested volume in whole blood.

Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject

Day(s) Performed

Monday through Sunday

Reference Values

Primidone

Therapeutic: 5.0-12.0 mcg/mL

Critical value: ≥15.0 mcg/mL

 

Phenobarbital

Therapeutic: 10.0-40.0 mcg/mL

Critical value: ≥60.0 mcg/mL

Clinical Information

Primidone is used for control of grand mal seizures that are refractory to other antiepileptics and seizures of psychomotor or focal origin.

 

Primidone is initially dosed in progressively increasing amounts starting with 100 mg at bedtime to 250 mg 3 times a day after 10 days of therapy in adults.

 

Primidone exhibits a volume of distribution of 0.6 L/kg and a half-life of 8 hours.

 

When monitoring primidone and phenobarbital levels simultaneously, the specimen should be drawn just before the next dose is administered.

 

Primidone is not highly protein bound, approximately 10%. Phenobarbital is a metabolite of primidone. Like phenobarbital, there are no known major drug-drug interactions that affect the pharmacology of primidone. Toxicity associated with primidone is primarily due to the accumulation of phenobarbital. Diagnosis and treatment are as described for PBAR / Phenobarbital, Serum.

Cautions

At the same time that the primidone level is monitored, one should also monitor the phenobarbital level, as phenobarbital is a metabolite of primidone.

Interpretation

At steady-state, which is achieved approximately 2 weeks after therapy is initiated, blood levels of primidone that correlate with optimal response to the drug range from 9.0 to 12.5 mcg/mL for adults and 7.0 to 10.0 mcg/mL for children <5 years of age.

 

The corresponding levels for phenobarbital are 20.0 to 40.0 mcg/mL for adults and 15.0 to 30.0 mcg/mL for children <5 years of age.

 

Dosage adjustment based on blood level information is the best way to obtain optimal response to the drug.

Reporting Name

Primidone and Phenobarbital, S

Method Name

PRIMD: Immunoassay

PBR: Kinetic Interaction of Microparticles in a Solution (KIMS)

Method Description

Primidone

The assay is a homogeneous enzyme immunoassay technique used for the analysis of specific compounds in biological fluids. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH (the reduced form of NAD), resulting in an absorbance change that is measured spectrophotometrically. Endogenous serum G6PDH does not interfere, because the coenzyme functions only with the bacterial (leuconostoc mesenteroides) enzyme employed in the assay.(Package insert: Seimens Primidone reagent, Seimens Healthcare Diagnostics Ltd., Newark, DE)

 

Phenobarbital

The assay is based on the kinetic interaction of microparticles in a solution (KIMS). Phenobarbital antibody is covalently coupled to microparticles and the drug derivative is linked to a macromolecule. The kinetic interaction of microparticles in solutions is induced by binding of drug-conjugate to the antibody on the microparticles and is inhibited by the presence o fphenobarbital in the sample. A competitive reaction takes place between the drug conjugate and phenobarbital in the serum sample for binding to the phenobarbital antibody on the microparticles. The resulting kinetic interaction of microparticles is indirectly proportional to the amount of drug present in the sample.(Package insert: Roche Phenobarbital reagent, Roche Diagnostic Corp, Indianapolis, IN)

CPT Code Information

PRIMD-80188

PBR-80184

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PRMB Primidone and Phenobarbital, S 10547-8

 

Result ID Test Result Name Result LOINC Value
PBR Phenobarbital, S 3948-7
PRIMD Primidone, S 3978-4

Report Available

Same day/1 day

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

Clinical Reference

Rall TW, Schleifer LS: Drugs effective in the therapy of the epilepsies: primidone. In Goodman and Gilman's The Pharmacological Basis of Therapeutics. Eighth edition. Edited by AG Gilman, TW Rall, AS Nies, P Taylor. New York, Pergamon Press, 1990, pp 446-447

Profile Information

Test ID Reporting Name Available Separately Always Performed
PRIMD Primidone, S No Yes
PBR Phenobarbital, S Yes Yes

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Neurology Specialty Testing Client Test Request (T732)

-Therapeutics Test Request (T831)